Literature DB >> 11437892

Visual cortex excitability in migraine with and without aura.

W M Mulleners1, E P Chronicle, J E Palmer, P J Koehler, J W Vredeveld.   

Abstract

OBJECTIVES: Previous research using transcranial magnetic stimulation has produced equivocal findings concerning thresholds for the generation of visual phosphenes in migraine with aura. These studies were methodologically varied and did not systematically address cortical excitability in migraine without aura. We therefore studied magnetophosphene thresholds in both migraine with aura and migraine without aura compared with headache-free controls.
METHODS: Sixteen subjects with migraine with aura and 12 subjects with migraine without aura were studied and compared with 16 sex- and age-matched controls. Using a standardized transcranial magnetic stimulation protocol of the occipital cortex, we assessed the threshold stimulation intensity at which subjects just perceived phosphenes via a method of alternating course and fine-tuning of stimulator output.
RESULTS: There were no significant differences across groups in the proportion of subjects seeing phosphenes. However, the mean threshold at which phosphenes were reported was significantly lower in both migraine groups (migraine with aura=47%, migraine without aura=46%) than in controls (66%). Moreover, there was no significant correlation between individual phosphene threshold and the time interval to the closest migraine attack.
CONCLUSION: Our findings confirm that the occipital cortex is hyperexcitable in the migraine interictum, both in migraine with and without aura.

Entities:  

Mesh:

Year:  2001        PMID: 11437892     DOI: 10.1046/j.1526-4610.2001.041006565.x

Source DB:  PubMed          Journal:  Headache        ISSN: 0017-8748            Impact factor:   5.887


  40 in total

1.  [Altered cerebral excitability and spreading depression. Causes for the comorbidity of epilepsy and migraine?].

Authors:  T Leniger; H C Diener; A Hufnagel
Journal:  Nervenarzt       Date:  2003-06-18       Impact factor: 1.214

2.  Local therapies in migraine.

Authors:  Marco Aguggia
Journal:  Neurol Sci       Date:  2009-05       Impact factor: 3.307

Review 3.  Headache and epilepsy.

Authors:  P R Bauer; J A Carpay; G M Terwindt; J W Sander; R J Thijs; J Haan; G H Visser
Journal:  Curr Pain Headache Rep       Date:  2013-08

4.  Current understanding of photophobia, visual networks and headaches.

Authors:  Rodrigo Noseda; David Copenhagen; Rami Burstein
Journal:  Cephalalgia       Date:  2018-06-25       Impact factor: 6.292

5.  Selective amplification of ipRGC signals accounts for interictal photophobia in migraine.

Authors:  Harrison McAdams; Eric A Kaiser; Aleksandra Igdalova; Edda B Haggerty; Brett Cucchiara; David H Brainard; Geoffrey K Aguirre
Journal:  Proc Natl Acad Sci U S A       Date:  2020-07-06       Impact factor: 11.205

6.  An inability to exclude visual noise in migraine.

Authors:  Marc S Tibber; Maria G Kelly; Ashok Jansari; Steven C Dakin; Alex J Shepherd
Journal:  Invest Ophthalmol Vis Sci       Date:  2014-04-17       Impact factor: 4.799

7.  Analytic information processing style in migraineurs.

Authors:  Francesco Di Sabato; Marzia Buonfiglio; Silvia Mandillo
Journal:  Neurol Sci       Date:  2012-09-19       Impact factor: 3.307

8.  Facilitatory effects of 1 Hz rTMS in motor cortex of patients affected by migraine with aura.

Authors:  Filippo Brighina; Giuseppe Giglia; Simona Scalia; Margherita Francolini; Antonio Palermo; Brigida Fierro
Journal:  Exp Brain Res       Date:  2004-10-12       Impact factor: 1.972

9.  Lack of cold pressor test-induced effect on visual-evoked potentials in migraine.

Authors:  Gianluca Coppola; Antonio Currà; Mariano Serrao; Cherubino Di Lorenzo; Manuela Gorini; Elisa Porretta; Alessia Alibardi; Vincenzo Parisi; Francesco Pierelli
Journal:  J Headache Pain       Date:  2009-12-10       Impact factor: 7.277

Review 10.  [Cortical dysbalance in the brain in migraineurs--hyperexcitability as the result of sensitisation?].

Authors:  A Stankewitz; A May
Journal:  Schmerz       Date:  2008-02       Impact factor: 1.107

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.